vs
Side-by-side financial comparison of REINSURANCE GROUP OF AMERICA INC (RGA) and Thermo Fisher Scientific (TMO). Click either name above to swap in a different company.
Thermo Fisher Scientific is the larger business by last-quarter revenue ($11.0B vs $6.6B, roughly 1.7× REINSURANCE GROUP OF AMERICA INC). Thermo Fisher Scientific runs the higher net margin — 15.0% vs 7.0%, a 8.1% gap on every dollar of revenue. On growth, REINSURANCE GROUP OF AMERICA INC posted the faster year-over-year revenue change (26.6% vs 6.2%). Over the past eight quarters, REINSURANCE GROUP OF AMERICA INC's revenue compounded faster (2.3% CAGR vs 2.2%).
Reinsurance Group of America, Incorporated is a holding company for a global life and health reinsurance entity based in Greater St. Louis within the western suburb of Chesterfield, Missouri, United States. With approximately $3.9 trillion of life reinsurance in force and assets of $118.7 billion as of December 31, 2024, RGA has grown to become the only international company to focus primarily on life and health-related reinsurance.
Thermo Fisher Scientific Inc. is an American life science and clinical research company. It is a global supplier of analytical instruments, clinical development solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006.
RGA vs TMO — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $6.6B | $11.0B |
| Net Profit | $463.0M | $1.7B |
| Gross Margin | — | — |
| Operating Margin | 7.7% | 16.9% |
| Net Margin | 7.0% | 15.0% |
| Revenue YoY | 26.6% | 6.2% |
| Net Profit YoY | 212.8% | 9.6% |
| EPS (diluted) | $6.91 | $4.43 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $11.0B | ||
| Q4 25 | $6.6B | $12.2B | ||
| Q3 25 | $6.2B | $11.1B | ||
| Q2 25 | $5.6B | $10.9B | ||
| Q1 25 | $5.3B | $10.4B | ||
| Q4 24 | $5.2B | $11.4B | ||
| Q3 24 | $5.7B | $10.6B | ||
| Q2 24 | $4.9B | $10.5B |
| Q1 26 | — | $1.7B | ||
| Q4 25 | $463.0M | $2.0B | ||
| Q3 25 | $253.0M | $1.6B | ||
| Q2 25 | $180.0M | $1.6B | ||
| Q1 25 | $286.0M | $1.5B | ||
| Q4 24 | $148.0M | $1.8B | ||
| Q3 24 | $156.0M | $1.6B | ||
| Q2 24 | $203.0M | $1.5B |
| Q1 26 | — | 16.9% | ||
| Q4 25 | 7.7% | 18.5% | ||
| Q3 25 | 5.2% | 17.5% | ||
| Q2 25 | 6.1% | 16.9% | ||
| Q1 25 | 7.0% | 16.6% | ||
| Q4 24 | 4.3% | 17.7% | ||
| Q3 24 | 3.8% | 17.3% | ||
| Q2 24 | 5.5% | 17.3% |
| Q1 26 | — | 15.0% | ||
| Q4 25 | 7.0% | 16.1% | ||
| Q3 25 | 4.1% | 14.5% | ||
| Q2 25 | 3.2% | 14.9% | ||
| Q1 25 | 5.4% | 14.6% | ||
| Q4 24 | 2.8% | 16.0% | ||
| Q3 24 | 2.8% | 15.4% | ||
| Q2 24 | 4.2% | 14.7% |
| Q1 26 | — | $4.43 | ||
| Q4 25 | $6.91 | $5.21 | ||
| Q3 25 | $3.81 | $4.27 | ||
| Q2 25 | $2.70 | $4.28 | ||
| Q1 25 | $4.27 | $3.98 | ||
| Q4 24 | $2.21 | $4.78 | ||
| Q3 24 | $2.33 | $4.25 | ||
| Q2 24 | $3.03 | $4.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.2B | $3.3B |
| Total DebtLower is stronger | $5.7B | — |
| Stockholders' EquityBook value | $13.5B | $51.9B |
| Total Assets | $156.6B | $113.3B |
| Debt / EquityLower = less leverage | 0.42× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $3.3B | ||
| Q4 25 | $4.2B | $10.1B | ||
| Q3 25 | $4.6B | $3.5B | ||
| Q2 25 | $5.4B | $6.4B | ||
| Q1 25 | $5.2B | $5.9B | ||
| Q4 24 | $3.3B | $5.6B | ||
| Q3 24 | $5.2B | $6.6B | ||
| Q2 24 | $4.6B | $8.8B |
| Q1 26 | — | — | ||
| Q4 25 | $5.7B | $35.9B | ||
| Q3 25 | $5.7B | $31.9B | ||
| Q2 25 | $5.7B | $33.0B | ||
| Q1 25 | $5.7B | $31.4B | ||
| Q4 24 | $5.0B | $29.1B | ||
| Q3 24 | $5.1B | $31.2B | ||
| Q2 24 | $5.1B | $30.3B |
| Q1 26 | — | $51.9B | ||
| Q4 25 | $13.5B | $53.4B | ||
| Q3 25 | $13.0B | $51.0B | ||
| Q2 25 | $12.1B | $50.5B | ||
| Q1 25 | $11.4B | $49.4B | ||
| Q4 24 | $10.8B | $49.6B | ||
| Q3 24 | $11.1B | $49.0B | ||
| Q2 24 | $9.7B | $47.4B |
| Q1 26 | — | $113.3B | ||
| Q4 25 | $156.6B | $110.3B | ||
| Q3 25 | $152.0B | $103.0B | ||
| Q2 25 | $133.5B | $101.2B | ||
| Q1 25 | $128.2B | $99.0B | ||
| Q4 24 | $118.7B | $97.3B | ||
| Q3 24 | $120.3B | $100.4B | ||
| Q2 24 | $109.9B | $98.5B |
| Q1 26 | — | — | ||
| Q4 25 | 0.42× | 0.67× | ||
| Q3 25 | 0.44× | 0.62× | ||
| Q2 25 | 0.48× | 0.65× | ||
| Q1 25 | 0.50× | 0.64× | ||
| Q4 24 | 0.47× | 0.59× | ||
| Q3 24 | 0.46× | 0.64× | ||
| Q2 24 | 0.52× | 0.64× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $7.3B | $1.2B |
| Free Cash FlowOCF − Capex | — | $825.0M |
| FCF MarginFCF / Revenue | — | 7.5% |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 15.83× | 0.72× |
| TTM Free Cash FlowTrailing 4 quarters | — | $6.8B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $1.2B | ||
| Q4 25 | $7.3B | $3.5B | ||
| Q3 25 | $-990.0M | $2.2B | ||
| Q2 25 | $-820.0M | $1.4B | ||
| Q1 25 | $-1.4B | $723.0M | ||
| Q4 24 | $17.1B | $3.3B | ||
| Q3 24 | $-1.1B | $2.2B | ||
| Q2 24 | $-967.0M | $2.0B |
| Q1 26 | — | $825.0M | ||
| Q4 25 | — | $3.0B | ||
| Q3 25 | — | $1.8B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $361.0M | ||
| Q4 24 | — | $2.8B | ||
| Q3 24 | — | $1.9B | ||
| Q2 24 | — | $1.7B |
| Q1 26 | — | 7.5% | ||
| Q4 25 | — | 24.5% | ||
| Q3 25 | — | 16.5% | ||
| Q2 25 | — | 10.2% | ||
| Q1 25 | — | 3.5% | ||
| Q4 24 | — | 24.7% | ||
| Q3 24 | — | 17.9% | ||
| Q2 24 | — | 15.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | 3.8% | ||
| Q3 25 | — | 3.6% | ||
| Q2 25 | — | 2.7% | ||
| Q1 25 | — | 3.5% | ||
| Q4 24 | — | 4.2% | ||
| Q3 24 | — | 2.6% | ||
| Q2 24 | — | 2.9% |
| Q1 26 | — | 0.72× | ||
| Q4 25 | 15.83× | 1.75× | ||
| Q3 25 | -3.91× | 1.39× | ||
| Q2 25 | -4.56× | 0.87× | ||
| Q1 25 | -5.00× | 0.48× | ||
| Q4 24 | 115.81× | 1.80× | ||
| Q3 24 | -6.84× | 1.33× | ||
| Q2 24 | -4.76× | 1.27× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RGA
Segment breakdown not available.
TMO
| Laboratory Products and Biopharma Services | $6.0B | 55% |
| Life Sciences Solutions | $2.6B | 24% |
| Analytical Instruments | $1.7B | 16% |
| Specialty Diagnostics | $1.1B | 10% |
